Log in with your email address username.

×

Attention doctorportal newsletter subscribers,

After December 2018, we will be moving elements from the doctorportal newsletter to MJA InSight newsletter and rebranding it to Insight+. If you’d like to continue to receive a newsletter covering the latest on research and perspectives in the medical industry, please subscribe to the Insight+ newsletter here.

As of January 2019, we will no longer be sending out the doctorportal email newsletter. The final issue of this newsletter will be distributed on 13 December 2018. Articles from this issue will be available to view online until 31 December 2018.

[Correspondence] ANTARCTIC: platelet function testing to adjust therapy – Authors’ reply

We thank Paul Gurbel and colleagues for their interest in our randomised ANTARCTIC study,1 but we think they have wrongly interpreted both the design and the results of the study. Their statement corresponds neither to the hypothesis nor to the primary endpoint of the study. We wish to underscore that the ANTARCTIC study was not a comparison between prasugrel and clopidogrel, that bleeding was not the primary endpoint, that the study never tested switching from prasugrel to clopidogrel, and that 5 mg is not a low dose but the approved dose of prasugrel for the elderly.

email